Flamel Technologies price target lowered to $17 from $22 at Roth Capital Roth Capital cut its price target on Flamel (FLML) after the FDA approved Fresenius Kabi's (FMS) New Drug Application for neostigmine methylsulfate, a drug which Flamel currently markets as Bloxiverz. Roth expects eostigmine to become a two player market, but adds that price increases by Flamel could mitigate the negative impacts on Flamel's growth. The firm keeps a Buy rating on Flamel.
JPMorgan to hold a conference 33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link